Purpose: We evaluated the use of magnetic resonance (MR) elastography (MRE) for staging liverˆbrosis in patients with chronic hepatitis C and compared the ability of MRE and serumˆbrosis markers for discriminating each stage ofˆbrosis.
Introduction
Chronic liver disease can lead to hepaticˆbrosis, cirrhosis, portal hypertension, and hepatocellular carcinoma. Management of patients with chronic liver disease requires knowledge of the stage of brosis because of its close association with prognosis and hepatocarcinogenesis. 1, 2 Liverˆbrosis stage is commonly determined by liver biopsy and assessment of the pathology-the only means of direct examination ofˆbrosis in tissue. However, liver biopsy is associated with such complication risks as hemorrhage and infection and inherent problems that include sampling error, high interobserver variability, and low patient acceptance. [3] [4] [5] Alternative noninvasive methods for evaluating liverˆbrosis have therefore been developed, which include the assessment of such proposed serum brosis markers as the aspartate aminotransferase (AST)/alanine aminotransferase (ALT) ratio (AAR), 6 the AST-to-platelet ratio index (APRI), 7 and the FIB-4 index. 8 Magnetic resonance (MR) elastography (MRE) was developed as a noninvasive method for measuring liver stiŠness and is currently used primarily for staging liverˆbrosis in the clinical setting. Though its su‹cient reproducibility [9] [10] [11] and high diagnostic ability for staging liverˆbrosis are reported, 12 previous studies of liver MRE have included cases of hepaticˆbrosis of various causes, including type B and C viral hepatitis and alcoholic hepa- 15 For example, pericellularˆbrosis is a distinguishing feature of alcoholic hepatitis,while periportal degeneration andˆbrosis is believed to be more prominant in type C viral hepatitis than alcoholic hepatitis. 16 Focal necrosis and in‰ammatory cell inˆltration are also believed to be more advanced in type B than type C viral hepatitis.
We evaluated MRE for staging liverˆbrosis in patients with type C chronic hepatitis and compared the discriminative ability of MRE and serum brosis markers, including the AAR, APRI, and FIB-4 index, at eachˆbrosis stage.
Materials and Methods

Patients
This retrospective study was performed in accordance with the principles of the Declaration of Helsinki. Our institutional review board approved the study, and written informed consent was obtained from all patients who underwent MRE. Between January 2010 and May 2012, 713 patients with chronic hepatic disease underwent MRE at our institution; all patients had undergone MR for liver cancer screening. Inclusion criteria for the study were: (1) type C chronic hepatitis, (2) available MRE data, (3) pathological determination of liver brosis stage within 2 months of MRE, and (4) available laboratory test results within one week of MRE. We excluded 5 patients with severe iron deposits in whom the T 2 * value of the liver was very low, which would preclude signal acquisition by MRE using a gradient-echo sequence. We also excluded patients with both type C and type B hepatitis (n＝4) or both type C and alcoholic hepatitis (n ＝1). After retrospectively matching radiological and pathological data, we identiˆed 114 patients who met the inclusion criteria (86 men, 28 women; aged 39 to 86 years, mean age 65.8±9.7 years). According to the pathological database of our institution, the diagnosis ofˆbrosis stage was conˆrmed by biopsy in 56 cases or resection in 58. Those reports were written by one of 3 diagnostic pathologists with 10 to 16 years' experience used by hematoxylin and eosin stain and Masson trichrome stain. The staging was performed using Metavir scoring system. The pathological stage of liver brosis was F0 in 3 patients, F1 in 15, F2 in 28, F3 in 25, and F4 in 43.
Serumˆbrosis markers
We calculated the values for the serumˆbrosis markers, the AAR, APRI, and FIB-4 index, using the following formulas, where ULN is the upper limit of normal AST level and PLT is the platelet
MR imaging
MRE was performed using a superconducting magnet operating at 1.5T (Signa EXCITE HD; GE Medical Systems, Milwaukee, WI, USA) and an 8-channel phased-array coil and before administration of contrast material. Images were obtained with patients in supine position using a cylindrical passive driver placed across the right chest wall to deliver vibrations via a transcostal approach. 17 The vibrator, placed outside the MR examination room, produced a pneumatic vibration that was delivered to the passive driver via a plastic cylinder. The passive driver was attached using a rubber belt to deliver the vibration to the patient's chest wall and the liver. The vibration generator and passive driver were developed at Mayo Clinic (Rochester, MN, USA).
A 2-dimensional gradient-echo MRE sequence was used. The images were acquired in the transverse plane. Scanning position was set above the gallbladder and below the subphrenic region of the liver. For acquisition of liver images at consistent positions at each phase oŠset, patients were asked to hold their breath after expiration. 12 The frequency of the driver was 60 Hz and the amplitude was 60z. A parallel imaging technique was not used. Table 1 shows other parameters. 
Analysis of liver stiŠness
The MR scanner automatically generates elastograms by processing the acquired propagating shear wave images according to an inversion algorithm previously described. 18, 19 Shear stiŠness of the tissue was determined as a pixel value (kPa). 19, 20 One of the authors (S.I.), with 8 years' radiology experience, referred to elastograms to place a region of interest (ROI) in the right lobe of the liver. We chose a slice near the center of the driver for ROI measurement because the traveling direction of the penetrating wave was considered parallel to the imaging plane around the driver center and because it is necessary to ensure that the wave travels along the imaging plane to avoid overestimation of the wavelength. ROIs were obtained for each patient, and the average value was recorded. As a rule, the ROI was at least 1.5 cm 2 and excluded blood vessels, the liver edge, and the area where interference by propagating waves was observed on phase images. One ROI was placed for each patient.
Statistical analysis
We calculated the mean and standard deviation (SD) of liver stiŠness and serumˆbrosis markers for each liverˆbrosis stage, F0, F1, F2, F3, and F4. We used Spearman's rank correlation coe‹cient to calculate the correlation coe‹cient betweenˆbrosis stage and these variables. Correlation was considered strong if the absolute value of the correlation coe‹cient (r) was greater than 0.7, moderate if r was 0.4 to 0.7, weak if r was 0.2 to 0.4, and absent if r was 0.2 or less.
We used receiver operating characteristic (ROC) curve analysis to assess the discriminative ability of MRE and serumˆbrosis markers. We calculated the area under the ROC curve (Az value) and optimal cutoŠ value for diŠerentiating AEF1 from F0, AEF2 from ÃF1, AEF3 from ÃF2, and F4 from ÃF3, and we calculated sensitivity and speciˆcity for the optimal cutoŠ value. We used a jackknife method to compare Az values of MRE, the AAR, the APRI, and the FIB-4 index for discriminatinĝ brosis stages. 21 We used JMP software (Ver. 10; SAS Institute, Cary, NC, USA) for all analyses. Pº0.05 was considered statistically signiˆcant.
Results
Mean stiŠness values of the liver increased as liverˆbrosis stage progressed: F0, 2.10±0.10 kPa; F1, 2.42±0.29 kPa; F2, 3.16±0.32 kPa; F3, 4.21 ±0.78 kPa; and F4, 6.20±1.08 kPa. The pathological stage of liverˆbrosis showed signiˆcant correlation with liver stiŠness values determined by MRE (r＝0.9149, Pº0.0001) but only moderate correlation with the APRI (r＝0.6035, Pº0.0001) and FIB-4 index (r＝0.4374, Pº0.0001) (Fig. 1a, c,  d ). No signiˆcant correlation was observed between the AAR andˆbrosis stage (r＝0.1019, P＝0.2806) (Fig. 1b) . Table 2 shows the mean Az values for discriminating liverˆbrosis stages using liver stiŠness values. The Az value for discriminating most liver brosis stages was signiˆcantly higher for MRE than the serumˆbrosis markers.
ROC analysis provided the optimal cutoŠ values of liver stiŠness for discriminating the stages of liverˆbrosis, and these values yielded sensitivity and speciˆcity for discriminatingˆbrosis stage (Table 3) . Figures 2 and 3 show the clinical cases.
Discussion
Staging of liverˆbrosis is important in managing chronic liver disease because prognosis diminishes and the risk of developing hepatocellular carcinoma increases asˆbrosis progresses. 1 Liver biopsy is the gold standard for assessing liverˆbrosis but carries some risk of complications, so many noninvasive alternative methods have been proposed. The simplest method for estimatingˆbrosis stage is to assess the serumˆbrosis markers, 22 but their reliability decreases when patients have no underlying liver disease or when their serum AST levels are normal. 23 Therefore, serum markers are associated with limited discriminative ability for staging liver brosis. Our study elucidated the superior discriminative ability for staging liverˆbrosis of MRE compared with serumˆbrosis markers, and Huwart and associates reported the signiˆcantly higher diagnostic ability of MRE than APRI for this staging. 13 A previous systematic review of the performance of serumˆbrosis markers showed the median Az values of serum markers for discriminating AEF2 ranging from 0.73 to 0.88 and for discriminating F4, from 0.73 to 0.94, 24 whereas Az values of MRE in our study were consistently above 0.97. We also conclude that MRE is superior to serum markers in its discriminative ability for staging liver brosis.
Other imaging-based methods proposed for staging liverˆbrosis include diŠusion-weighted imaging and an uptake index evaluating gadoxetic acid-enhanced hepatocyte-phase images. [25] [26] [27] [28] These methods do not measure liver stiŠness, but other param-eters, such as molecular diŠusivity, tissue microperfusion, and hepatocyte function. However, some authors suggest that the diagnostic abilities of these methods are insu‹cient compared with those of serum markers or MRE. [29] [30] [31] Our study has some major limitations. First, we did not analyze other factors that might in‰uence liver stiŠness, including steatosis, edema, iron overload, and portal/arterial ‰ow. Although steatosis itself might not aŠect the stiŠness measurement, fat deposition can cause in‰ammation, which, in turn, can increase liver stiŠness even in the absence of brosis. 32, 33 The in‰uence of these factors should be further studied in larger series. However, a previous study suggested a signiˆcant correlation of liver stiŠness measured by transient ultrasound elastography withˆbrosis but not with in‰ammatory activity and steatosis. 34 A second limitation was that we had only a small number of cases of F0 and F1 because the clinical requirement for performing biopsy to evaluateˆbrosis stage during early-stage liver disease is minimal. Another limitation was the diagnosis ofˆbrosis stage by only one of 3 pathologists rather than by consensus. Liver biopsy is limited by such factors as high inter-and intraobserver variability, 3-5 but we could not examine the reproducibility of pathological stage of liverˆbro-sis. Finally, we did not compare type C viral hepatitis with other hepatitis because there were insufcient cases of other hepatitis. We will try to compare them in the future.
Conclusion
In conclusion, MRE is a reliable technique for staging liverˆbrosis and discriminating liverˆbro-sis stages in patients with chronic hepatitis C.
